May 1, 2009 · Topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder. Recently, a crucial role was proposed for the IL-23/IL-17 axis in psoriasis.

Mouse strains differ in their baseline characteristics but macroscopic IMQ responses are consistent. Mouse back skin was treated with 62.5 mg Aldara™ (5% IMQ) or a non-toxic lanolin-derived occlusion cream (CTL) once per day for five consecutive days.

One of the most widely approved psoriasis-like animal models is the imiquimod (IMQ)-induced mouse model. This representation mimics various aspects of the complex cutaneous pathology and could be appropriate for testing topical treatment options.

May 1, 2009 · Topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder. Recently, a crucial role was proposed for the IL-23/IL-17 axis in psoriasis.

Jan 28, 2021 · By consecutive 7-day-treatment with 42.5 mg of IMQ on female C57BL/6 mice, distinct psoriatic lesion was induced on the back skin with the severity peaked on day 5; disease progression and efficacy of the tested articles could be determined by several qualitative and quantitative indices.

However, digoxin treatment increased the IMQ-induced back skin thickening at day 6 (1.13 vs. 0.94 mm, p<0.01; Fig. 1C), and increased erythema and scaling on the back skin (sum score 6.6 vs. 5.4, p<0.05; Fig. 1C).

The most commonly used model for the disease is the Imiquimod-induced skin inflammation model (IMQ-model). In the IMQ model, Aldara cream (containing 5% IMQ) is applied topically to the ear and shaved back skin on mice daily.

Imiquimod (IMQ) produces a cutaneous phenotype in mice frequently studied as an acute model of human psoriasis. IMQ is a Toll-like Receptor (TLR7) agonist that can be applied to mouse skin to elicit erythema, scaling, epidermis hyperplasia, …

JAX offers preclinical imiquimod-induced psoriasis mouse models as a rapid screening approach for candidate psoriatic therapies. Imiquimod (IMQ) is a toll-like receptor agonist that acts as an immune response modifier.

To induce disease, imiquimod is applied to the ear and back of mice daily for 5 days (Days 0 to 4). Treatment may be prophylactic, or therapeutic, usually starting 2 days after initial imiquimod application.